Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib plus Avelumab maintenance in metastatic bladder cancer
NCT05687721Phase 2Withdrawn
- Sponsor
- VA Office of Research & Development
- Start
- Jun 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib in urothelial carcinoma (UC), sponsored by VA Office of Research & Development. Primary endpoint: Progression-free survival at 6 months. Planned start Jun 2025; status: withdrawn.
02
Drugs
copanlisib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05687721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05687721.